SSRI and Buprenorphine

This study has been completed.
Information provided by (Responsible Party):
Michael Stein, MD, Butler Hospital Identifier:
First received: May 18, 2007
Last updated: March 5, 2012
Last verified: March 2012
This study is designed to test whether treatment of depressive symptoms using escitalopram improves adherence to Buprenorphine and reduces symptoms of depression for individuals receiving Buprenorphine through their medical provider.

Condition Intervention Phase
Opiate Dependence
Drug: escitalopram
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Antidepressants During Office-Based Buprenorphine

Resource links provided by NLM:

Further study details as provided by Butler Hospital:

Primary Outcome Measures:
  • Percentage of Participants Who Dropped Out of Buprenorphine Treatment [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Drop-out is defined as 7 or more days of missed Buprenorphine doses

Secondary Outcome Measures:
  • Depressive Symptoms [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Depressive symptoms, as measured by self-report during study interviews, using the Beck Depression Inventory II. Scores ranged from 0-63; higher scores indicate more depressive symptoms.

Enrollment: 147
Study Start Date: December 2006
Study Completion Date: September 2009
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: placebo Drug: placebo
placebo capsule/day for 3 months
Active Comparator: escitalopram Drug: escitalopram
10mg escitalopram/day for 3 months

Detailed Description:
Participants interested in receiving Buprenorphine will be offered the opportunity to enroll in this study. Enrolled study participants will complete interviews at baseline and again every two weeks for a total of 8 interviews over 3 months. In this double-blind randomized controlled trial, participants will either receive a placebo or escitalopram (10mg). All participants will also be followed by their Buprenorphine clinic medical provider. Questions during the face-to-face interviews will assess mood, drug craving, pain, sleep, medication adherence and drug-related experiences. Comparison(s): Participants randomized into the medication component of the study as compared to participants randomized into the placebo component of the study.

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • opiate dependence
  • Ham-D > 14

Exclusion Criteria:

  • no psychiatric contraindications to using escitalopram
  • no medical contraindications to using escitalopram
  • methadone dose < 30
  • no current SSRI use
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00475878

United States, Rhode Island
Butler Hospital
Providence, Rhode Island, United States, 02906
Sponsors and Collaborators
Butler Hospital
Principal Investigator: Michael D Stein, M.D. Rhode Island Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):

Responsible Party: Michael Stein, MD, Principal Investigator, Butler Hospital Identifier: NCT00475878     History of Changes
Other Study ID Numbers: DA022207  0807-002 
Study First Received: May 18, 2007
Results First Received: June 28, 2011
Last Updated: March 5, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Butler Hospital:
opiate use

Additional relevant MeSH terms:
Analgesics, Opioid
Anti-Dyskinesia Agents
Antidepressive Agents
Antidepressive Agents, Second-Generation
Antiparkinson Agents
Autonomic Agents
Central Nervous System Depressants
Cholinergic Agents
Cholinergic Antagonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Narcotic Antagonists
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Physiological Effects of Drugs
Psychotropic Drugs
Sensory System Agents
Serotonin Agents
Serotonin Uptake Inhibitors processed this record on May 22, 2016